vs

Side-by-side financial comparison of INVO Fertility, Inc. (IVF) and Vuzix Corp (VUZI). Click either name above to swap in a different company.

Vuzix Corp is the larger business by last-quarter revenue ($2.2M vs $1.8M, roughly 1.3× INVO Fertility, Inc.). INVO Fertility, Inc. runs the higher net margin — -150.5% vs -384.2%, a 233.6% gap on every dollar of revenue. On growth, Vuzix Corp posted the faster year-over-year revenue change (76.4% vs 22.6%). INVO Fertility, Inc. produced more free cash flow last quarter ($-1.8M vs $-5.9M). Over the past eight quarters, INVO Fertility, Inc.'s revenue compounded faster (12.8% CAGR vs 5.8%).

INVO Fertility, Inc. is a specialized healthcare company focused on delivering accessible assisted reproductive technology solutions. It develops, manufactures and markets the patented INVOcell intravaginal culture system for in vitro fertilization procedures, serving fertility clinics and patients across North America, Europe and other global regions, with a mission to reduce barriers to high-quality fertility care.

Vuzix Corporation is an American multinational technology company headquartered in Rochester, New York and founded by Paul Travers in 1997. Vuzix is a supplier of smartglasses and augmented reality display technology. Vuzix manufactures and sells computer display devices and software. Vuzix head-mounted displays are marketed towards mobile and immersive augmented reality applications, such as 3D gaming, manufacturing training, and military tactical equipment. On January 5, 2015, Intel acquire...

IVF vs VUZI — Head-to-Head

Bigger by revenue
VUZI
VUZI
1.3× larger
VUZI
$2.2M
$1.8M
IVF
Growing faster (revenue YoY)
VUZI
VUZI
+53.8% gap
VUZI
76.4%
22.6%
IVF
Higher net margin
IVF
IVF
233.6% more per $
IVF
-150.5%
-384.2%
VUZI
More free cash flow
IVF
IVF
$4.1M more FCF
IVF
$-1.8M
$-5.9M
VUZI
Faster 2-yr revenue CAGR
IVF
IVF
Annualised
IVF
12.8%
5.8%
VUZI

Income Statement — Q3 FY2025 vs Q4 FY2025

Metric
IVF
IVF
VUZI
VUZI
Revenue
$1.8M
$2.2M
Net Profit
$-2.6M
$-8.6M
Gross Margin
16.7%
Operating Margin
-93.1%
-373.9%
Net Margin
-150.5%
-384.2%
Revenue YoY
22.6%
76.4%
Net Profit YoY
-62.2%
36.9%
EPS (diluted)
$-0.77
$-0.12

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
IVF
IVF
VUZI
VUZI
Q4 25
$2.2M
Q3 25
$1.8M
$1.2M
Q2 25
$1.9M
$1.3M
Q1 25
$1.6M
$1.6M
Q4 24
$1.7M
$1.3M
Q3 24
$1.4M
$1.4M
Q2 24
$1.8M
$1.1M
Q1 24
$1.6M
$2.0M
Net Profit
IVF
IVF
VUZI
VUZI
Q4 25
$-8.6M
Q3 25
$-2.6M
$-7.4M
Q2 25
$-5.3M
$-7.7M
Q1 25
$-17.4M
$-8.6M
Q4 24
$-3.6M
$-13.7M
Q3 24
$-1.6M
$-9.2M
Q2 24
$-2.2M
$-40.6M
Q1 24
$-1.6M
$-10.0M
Gross Margin
IVF
IVF
VUZI
VUZI
Q4 25
16.7%
Q3 25
-35.4%
Q2 25
-58.7%
Q1 25
35.2%
-16.8%
Q4 24
41.4%
-389.6%
Q3 24
31.0%
-18.8%
Q2 24
53.1%
-30.5%
Q1 24
45.3%
-2.6%
Operating Margin
IVF
IVF
VUZI
VUZI
Q4 25
-373.9%
Q3 25
-93.1%
-645.5%
Q2 25
-160.4%
-606.1%
Q1 25
-1042.1%
-555.0%
Q4 24
-202.0%
-1089.2%
Q3 24
-90.7%
-670.9%
Q2 24
-100.9%
-3726.5%
Q1 24
-95.7%
-503.6%
Net Margin
IVF
IVF
VUZI
VUZI
Q4 25
-384.2%
Q3 25
-150.5%
-633.4%
Q2 25
-283.6%
-591.5%
Q1 25
-1060.1%
-546.4%
Q4 24
-211.3%
-1074.0%
Q3 24
-113.8%
-665.4%
Q2 24
-122.2%
-3715.6%
Q1 24
-101.3%
-501.4%
EPS (diluted)
IVF
IVF
VUZI
VUZI
Q4 25
$-0.12
Q3 25
$-0.77
$-0.09
Q2 25
$-13.30
$-0.10
Q1 25
$-12.53
$-0.11
Q4 24
$14.86
$-0.16
Q3 24
$-15.11
$-0.14
Q2 24
$-22.39
$-0.62
Q1 24
$-7.55
$-0.16

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
IVF
IVF
VUZI
VUZI
Cash + ST InvestmentsLiquidity on hand
$21.2M
Total DebtLower is stronger
$2.0M
Stockholders' EquityBook value
$5.8M
$24.7M
Total Assets
$18.8M
$40.1M
Debt / EquityLower = less leverage
0.34×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
IVF
IVF
VUZI
VUZI
Q4 25
$21.2M
Q3 25
$22.6M
Q2 25
$17.5M
Q1 25
$15.2M
Q4 24
$18.2M
Q3 24
$14.3M
Q2 24
$9.9M
Q1 24
$16.5M
Total Debt
IVF
IVF
VUZI
VUZI
Q4 25
Q3 25
$2.0M
Q2 25
$4.8M
Q1 25
Q4 24
$7.5M
Q3 24
Q2 24
Q1 24
Stockholders' Equity
IVF
IVF
VUZI
VUZI
Q4 25
$24.7M
Q3 25
$5.8M
$27.9M
Q2 25
$2.6M
$28.9M
Q1 25
$3.3M
$32.8M
Q4 24
$12.7M
$37.3M
Q3 24
$-23.3K
$39.6M
Q2 24
$1.4M
$35.4M
Q1 24
$10.2K
$73.1M
Total Assets
IVF
IVF
VUZI
VUZI
Q4 25
$40.1M
Q3 25
$18.8M
$42.5M
Q2 25
$19.3M
$36.9M
Q1 25
$31.7M
$35.8M
Q4 24
$46.4M
$39.4M
Q3 24
$17.0M
$41.8M
Q2 24
$17.8M
$38.2M
Q1 24
$17.3M
$77.0M
Debt / Equity
IVF
IVF
VUZI
VUZI
Q4 25
Q3 25
0.34×
Q2 25
1.83×
Q1 25
Q4 24
0.59×
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
IVF
IVF
VUZI
VUZI
Operating Cash FlowLast quarter
$-1.8M
$-5.6M
Free Cash FlowOCF − Capex
$-1.8M
$-5.9M
FCF MarginFCF / Revenue
-101.6%
-263.5%
Capex IntensityCapex / Revenue
0.5%
15.8%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-7.8M
$-20.8M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
IVF
IVF
VUZI
VUZI
Q4 25
$-5.6M
Q3 25
$-1.8M
$-5.0M
Q2 25
$-1.7M
$-4.8M
Q1 25
$-3.5M
$-3.5M
Q4 24
$-617.4K
$-4.0M
Q3 24
$-640.8K
$-5.3M
Q2 24
$-1.5M
$-5.6M
Q1 24
$-260.6K
$-8.8M
Free Cash Flow
IVF
IVF
VUZI
VUZI
Q4 25
$-5.9M
Q3 25
$-1.8M
$-5.3M
Q2 25
$-1.7M
$-5.5M
Q1 25
$-3.6M
$-4.1M
Q4 24
$-696.3K
$-4.3M
Q3 24
$-5.5M
Q2 24
$-1.5M
$-6.5M
Q1 24
$-310.3K
$-8.9M
FCF Margin
IVF
IVF
VUZI
VUZI
Q4 25
-263.5%
Q3 25
-101.6%
-457.4%
Q2 25
-92.6%
-425.6%
Q1 25
-216.9%
-257.2%
Q4 24
-40.6%
-334.4%
Q3 24
-395.1%
Q2 24
-82.3%
-591.4%
Q1 24
-19.7%
-444.4%
Capex Intensity
IVF
IVF
VUZI
VUZI
Q4 25
15.8%
Q3 25
0.5%
27.4%
Q2 25
0.5%
56.1%
Q1 25
0.9%
38.8%
Q4 24
4.6%
18.1%
Q3 24
0.0%
14.4%
Q2 24
3.0%
75.8%
Q1 24
3.2%
5.1%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons